TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Consecutive number of intrusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of distress evoked by the intrusions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in severity of PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with the induction method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart rate variability (high-frequency component)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fever episodes
Endpoint domain: Adverse events/effects
Primary endpoint: BNP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricle function (ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to work and normal activity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FIM score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Papillary conjunctivitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: musculoskeletal symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lower extremity function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Beneficial effect of cyclosporine 0.05% ophthalmic emulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median survival based on CA-125 levels
Endpoint domain: Mortality/survival
Primary endpoint: Rate of complete evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improvement in residual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hb value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: improvement in thoracic range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients receiving properly timed antimicrobial prophylaxis dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic accuracy of ThinPrep technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD-RS-5 total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new or progressive AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to resolution of DKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)‐D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diuretic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: dyspnea relief
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: lean mass (LM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle area (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant improvement in angina severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median amprenavir concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lopinavir inhibitory quotient and virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall improvement of VKC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival discharge reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photophobia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial thickness in late follicular phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Postpartum depressive symptoms screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-four-hour tramadol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lequesne OA index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worsening of the ulcer
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage healing difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in DRSP symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful intubation on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average duration of successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glottic exposure (Cormack and Lehane grade)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary protein reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary red-cell count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: resolution of lesions and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-lymphocyte function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocytes expressing HLA-DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MAS (Modified Ashworth Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Brunnstrom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Temperature values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory markers (IL‐6 and TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Multidimensional Fatigue Inventory (MFI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Preventable hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Preventable emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean weekly minutes of moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in survivorship information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in survivorship care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fathers' limit setting
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reinforcement for multiple lifestyle behaviours
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean number of T2w-Sub lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative number of new Gd-T1w lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: hospitalization or emergency room (ER) visit for HF
Endpoint domain: Mortality/survival
Primary endpoint: clinical disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general well-being score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: early ST-segment elevation resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: grade 3 myocardial blush
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular wall motion score index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of DH-AVB post-TAVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of days alive without delirium or coma
Endpoint domain: Mortality/survival
Primary endpoint: mean number of cumulus-oocyte complexes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in Ham-D-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients classified as responders (50% decrease from baseline Ham-D-17 scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients in remission (Ham-D-17 score of 7 or less)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean LGE scar percentage (LGE%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average ECV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative PHQ‐9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean blood glucose level at 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 500 g pressure displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy absorption ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local soft tissue tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuromotor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: error-free records
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correctly entered data fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of narcotics required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healing of erosive oesophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Night-time heartburn and regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete elimination of symptoms of gastro-oesophageal reflux disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: frequency of abnormal laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of ZDV resistance
Endpoint domain: Adverse events/effects
Primary endpoint: visual-spatial memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: verbal fluency improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: speeded dexterity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in sebum production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical improvement in acneic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global rating of treatment effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Zinc metabolism (ZnS and ZnU levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emergency department visits due to asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D-3L mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ-5D-3L anxiety/depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall eradication of H pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cold symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: collagen density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Calprotectin Concentrations (FCCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Triglyceride (TRG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incisional hernia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression of left ventricular remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: self-reported high-risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Communication with children about targeted risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy to discuss pubertal development and sexuality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived influence over youths' behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Hamilton score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jumping height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee angular velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower limb loading symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child/parent agreement in health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Child/parent agreement in health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in high-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total cholesterol elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting triglyceride elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of interruptions of radiotherapy due to myelotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 2-hour postprandial glucose excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nondiagnostic distension score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total peripheral resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Children's compromised physical growth (weight and height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internalizing and externalizing symptoms of behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of test in differentiating placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No longer had a diagnosis of social phobia
Endpoint domain: Mortality/survival
Primary endpoint: mean HDRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA < 100,000 copies/ml rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine aminotransferase normalization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Service utilization rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for administration of local anesthesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Stroke or death rate
Endpoint domain: Mortality/survival
Primary endpoint: Eradication rates of Helicobacter pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: KAP-values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation exposure outcomes
Primary endpoint: peak skin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation exposure outcomes
Primary endpoint: cancer risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: Cure rate of sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women remaining malaria-free during pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of malaria episodes per 100 person-years
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of parasitemia
Endpoint domain: Adverse events/effects
Primary endpoint: myocardial infarction risk
Endpoint domain: Mortality/survival
Primary endpoint: total death risk
Endpoint domain: Mortality/survival
Primary endpoint: cardiac death risk
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of acute postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malar height reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net use of fans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABL improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-discharge death
Endpoint domain: Mortality/survival
Primary endpoint: Rates of BI performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported past-month drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescription according to CPG recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bodily pain improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vitality improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary success rate of selective common bile duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in risk of oxytocin stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean loss of QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HbA1c coefficient of failure (CoF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SCD/ICD shock
Endpoint domain: Mortality/survival
Primary endpoint: Soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pink aesthetic score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NT-proBNP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with labor management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cure rate of severe Clostridium difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent rate of depression
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of atelectasis and pleural effusion
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage plaque coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma level of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AST and ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood cell elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Striatal SERT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurotransmitter outcomes